TN2019000004A1 - Vita, chemotherapy treatment for several types of cancer and without major and moderate side effects. - Google Patents
Vita, chemotherapy treatment for several types of cancer and without major and moderate side effects.Info
- Publication number
- TN2019000004A1 TN2019000004A1 TNP/2019/000004A TN2019000004A TN2019000004A1 TN 2019000004 A1 TN2019000004 A1 TN 2019000004A1 TN 2019000004 A TN2019000004 A TN 2019000004A TN 2019000004 A1 TN2019000004 A1 TN 2019000004A1
- Authority
- TN
- Tunisia
- Prior art keywords
- cancer
- treatment
- formula
- vita
- major
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 7
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 238000002512 chemotherapy Methods 0.000 title 1
- 230000030833 cell death Effects 0.000 abstract 2
- 238000002474 experimental method Methods 0.000 abstract 2
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 239000003124 biologic agent Substances 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000001514 prostate carcinoma Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
La combinaison innovante des différents agents biologiques a permis l'élaboration d'une formule traitante sous forme de perfusion intraveineuse, pour le traitement de six (6) types de cancer qui sont : Le cancer du tissu mammaire Le cancer de l'ovaire Le cancer de la prostate Le cancer de l'estomac Le cancer de la vessie La procédure d'expérimentation était préparée durant 40 mois. L'expérimentation de la formule était réalisée en comparaison avec le traitement «cisplatine» de MYLAN et le traitement «5-fluouracile» de TEVA. Ce traitement est favorisé par rapport les autres traitements sur le marché car il assure la provocation de la procédure de la mort cellulaire des cellules cancéreuse durant une durée plus courte que la durée de la mort cellulaire en utilisant les autres formules. Aussi, la formulation de VITA provoque l'apoptose cellulaire «sélectif» sans les effets negatifs majeurs et moyens. Cette formule est destinée strictement pour l'industrie pharmaceutique.The innovative combination of different biological agents has made it possible to develop a treatment formula in the form of an intravenous infusion, for the treatment of six (6) types of cancer which are: Cancer of the mammary tissue Cancer of the ovary Cancer of the prostate Stomach cancer Bladder cancer The experimental procedure was prepared for 40 months. The experiment with the formula was carried out in comparison with the “cisplatin” treatment from MYLAN and the “5-fluouracil” treatment from TEVA. This treatment is favored over other treatments in the market because it ensures the provocation of the cell death procedure of cancer cells for a shorter time than the time of cell death using the other formulas. Also, the formulation of VITA causes "selective" cell apoptosis without major and moderate negative effects. This formula is intended strictly for the pharmaceutical industry.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TNP/2019/000004A TN2019000004A1 (en) | 2019-01-08 | 2019-01-08 | Vita, chemotherapy treatment for several types of cancer and without major and moderate side effects. |
| PCT/TN2019/000008 WO2020145905A1 (en) | 2019-01-08 | 2019-02-19 | Vita, the chemotherapy treatment for several types of cancer and without major and moderate side effects |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TNP/2019/000004A TN2019000004A1 (en) | 2019-01-08 | 2019-01-08 | Vita, chemotherapy treatment for several types of cancer and without major and moderate side effects. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2019000004A1 true TN2019000004A1 (en) | 2020-07-15 |
Family
ID=66484117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP/2019/000004A TN2019000004A1 (en) | 2019-01-08 | 2019-01-08 | Vita, chemotherapy treatment for several types of cancer and without major and moderate side effects. |
Country Status (2)
| Country | Link |
|---|---|
| TN (1) | TN2019000004A1 (en) |
| WO (1) | WO2020145905A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002055106A2 (en) * | 2001-01-09 | 2002-07-18 | Merck Patent Gmbh | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
| US20060293264A1 (en) * | 2004-07-22 | 2006-12-28 | Grandis Jennifer R | STAT3 decoy oligonucleotides and uses therefor |
| WO2008013966A2 (en) * | 2006-07-28 | 2008-01-31 | Johns Hopkins University | Use of 8-quinolinol and its analogs to target cancer stem cells |
-
2019
- 2019-01-08 TN TNP/2019/000004A patent/TN2019000004A1/en unknown
- 2019-02-19 WO PCT/TN2019/000008 patent/WO2020145905A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020145905A1 (en) | 2020-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Banerjee et al. | Efficacy of selected natural products as therapeutic agents against cancer | |
| CN104042618B (en) | The treatment of malignant hematologic disease | |
| EP3034076B1 (en) | Combined application of isothiocyanate compound and anti-cancer medicine | |
| CN1338932A (en) | Use of lipoic acid combination with ascorbic acid in the treatment of cancer | |
| US20210338686A1 (en) | Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent | |
| CN109692326A (en) | A kind of application of bee venom lipidic nanoparticles | |
| RU2057528C1 (en) | Method of malignant tumor chemotherapy | |
| WO2015172712A1 (en) | Pharmaceutical composition for injection with synergistic effect of vitamin c and antitumour drugs | |
| CN1681489A (en) | Combination of chemotherapeutic drugs for increasing antitumor activity | |
| ES2656913T3 (en) | Endrogenin A and antineoplastic agents for the treatment of chemosensitive or chemoresistant tumors | |
| TN2019000004A1 (en) | Vita, chemotherapy treatment for several types of cancer and without major and moderate side effects. | |
| CN101920015A (en) | A kind of pharmaceutical composition for treating cancer | |
| WO2021169974A1 (en) | Combined pharmaceutical composition for resisting double-hit lymphomas, and use thereof | |
| JPS6212716A (en) | Carcinostatic agent | |
| CN109419803A (en) | Cell autophagy inhibitor and Afatinib pharmaceutical composition and its purposes in preparation tumour Synergistic preparations | |
| EA014603B1 (en) | Anti-tumoral, antibacterial and antiviral pharmaceutical composition (variants) | |
| Teicher et al. | Acute in vivo resistance in high-dose therapy. | |
| JPS60501408A (en) | Methods and agents for increasing animal tolerance to oxidant stress-inducing antibiotics | |
| Dréau et al. | Inhibitory effects of fusarochromanone on melanoma growth | |
| CN1972955B (en) | radiosensitizer | |
| Ning et al. | Combination therapy: lonidamine, hyperthermia, and chemotherapy against the RIF-1 tumor in vivo | |
| Tabaru et al. | Treatment of VX2 carcinoma implanted in the liver with arterial and intraperitoneal administration of oily anticancer agents. | |
| JP2021533107A (en) | Combination therapy to treat cancer | |
| ES2415907T3 (en) | Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents | |
| US20100280125A1 (en) | Medicinal agent |